Recommending analgesics for people with asthma

Area of Science:

• Pharmacology
• Allergy and Immunology
• Respiratory Medicine

Background:

• Asthma affects 7% globally, with higher prevalence in Australia (10% adults, 20% children).
• Aspirin sensitivity, causing urticaria, angioedema, or rhinitis, affects 0.3% generally but up to 20% of asthmatics.
• Cross-sensitivity is common with nonsteroidal anti-inflammatory drugs (NSAIDs) inhibiting cyclooxygenase.

Purpose of the Study:

• To highlight the increased risk of NSAID sensitivity in asthma patients.
• To emphasize the safety of paracetamol (acetaminophen) in this population.
• To advocate for proactive healthcare provider counseling regarding analgesic choices for asthmatics.

Main Methods:

• Literature review on asthma prevalence and analgesic sensitivity.
• Analysis of NSAID cross-reactivity and paracetamol's safety profile.
• Discussion of diagnostic challenges and clinical management strategies.

Main Results:

• Asthmatics are at significantly higher risk (up to 20%) for aspirin and NSAID sensitivity compared to the general population.
• Paracetamol (acetaminophen) is rarely associated with cross-sensitivity in asthma patients.
• Predicting sensitivity is difficult, and provocation tests are the definitive diagnostic method.

Conclusions:

• Healthcare providers should proactively screen asthma patients for potential aspirin/NSAID sensitivity.
• Counseling patients on risks and recommending safer alternatives like paracetamol is crucial.
• Informed analgesic choices can prevent adverse reactions in individuals with asthma.